Over-expression studies have demonstrated that RALT (receptor associated late transducer) is a feedback inhibitor of ErbB-2 mitogenic and transforming signals. In growth-arrested cells, expression of endogenous RALT is induced by mitogenic stimuli, is high throughout mid to late G1 and returns to baseline as cells move into S phase. Here, we show that physiological levels of RALT effectively suppress ErbB-2 mitogenic signals. We also investigate the regulatory mechanisms that preside to the control of RALT expression. We demonstrate that pharmacological ablation of extracellular signal-regulated kinase (ERK) activation leads to blockade of RALT expression, unlike genetic and/or pharmacological interference with the activities of PKC, Src family kinases, p38 SAPK and PI-3K. Tamoxifen-dependent activation of an inducible Raf : ER chimera was sufficient to induce RALT expression. Thus, activation of the Ras -Raf -ERK pathway is necessary and sufficient to drive RALT expression. The RALT protein is labile and was found to accumulate robustly upon pharmacological inhibition of the proteasome. We were able to detect ubiquitinconjugated RALT species in living cells, suggesting that ubiquitinylation targets RALT for proteasome-dependent degradation. Such an integrated transcriptional and posttranslational control is likely to provide RALT with the ability to fluctuate timely in order to tune ErbB signals.
Introduction
Receptor tyrosine kinases (RTKs) regulate the execution of fundamental cellular processes by activating enzymes and transcriptional regulators via a complex network of protein -protein interactions (Schlessinger, 2000) . In a given cell type, structurally different RTKs may activate different signaling pathways, thus implementing distinct cellular programs (Schlessinger, 2000) . Such a purely qualitative model has been disputed by the observation that RTKs belonging to various families may activate broadly overlapping sets of signal transducers and yet regulate divergent programs in the same cell type (Simon, 2000) . It is now clear that differences in strength and duration of a given RTK signal are themselves a determinant of signal identity and signal specificity (Perrimon and McMahon, 1999; Simon, 2000) . For instance, graded activation of extracellular signal-regulated kinase (ERK) by the Torso RTK at the posterior pole of the Drosophila embryo is translated into different transcriptional responses, that, in turn, induce distinct morphogenetic programs (Ghiglione et al., 1999; Greenwood and Struhl, 1997) . A somewhat similar scenario is observed in mammalian PC12 cells: a transient wave of ERK activity elicited by EGF stimulation allows PC12 cells to proliferate, whereas sustained activation of the Ras -ERK pathway by nerve growth factor (NGF) leads to neuronal differentiation (Marshall, 1995) .
Besides being crucial to developmental decisions, graded RTK activity also regulates tissue homeostasis in post-natal life. For instance, physiological oscillations of RTK activity may dictate the choice between cell survival and cell multiplication (Flanagan and Lader, 1998) . On the other hand, abnormal mitogenic stimulation may cause cells to undergo cell cycle arrest rather than proceed to cell division (Woods et al., 1997) , a process which is believed to protect cells from oncogenic stimuli (McMahon and Woods, 2001) .
Based on the above premise, the identification of mechanisms devoted to the control of RTK outputs is drawing increasing attention. Developmental studies indicate that negative regulation of RTK signals has evolved as a fundamental means for the cell to set thresholds of RTK signals and monitor their intensity and duration (Freeman, 2000; Moghal and Sternberg, 1999) . Current thinking, largely derived from genetic studies in worms and flies, holds that one class of RTK inhibitors, such as Cbl (Yoon et al., 1995; Pai et al., 2000) , modulates RTK function since the inception of receptor triggering, thus setting thresholds and boundaries of RTK activity ab initio. Feedback inhibitors such as Kekkon1, Argos and Sprouty, on the other hand, are only expressed in the context of transcriptional responses triggered by RTK activity and further refine RTK signals (Freeman, 2000; Perrimon and McMahon, 1999) . Because transcriptional activation of genes encoding RTK feedback inhibitors gauges the accumulation of receptor signals, it is believed that tuning of RTK activity by feedback inhibitors provides for accurate reproducibility in time and space of defined kinetics of RTK outputs (Freeman, 2000; Perrimon and McMahon, 1999) .
Our understanding of negative signaling to mammalian RTKs is still rudimentary and its complexity is likely to be underestimated. Yet, a few paradigms have surfaced which so far largely recapitulate those established in invertebrates. Thus, Cbl emerges as an essential receptor -proximal element of the molecular machinery that governs RTK internalization and degradation (Waterman and Yarden, 2001) . Feedback inhibitors such as SOCS proteins (Krebs and Hilton, 2001 ) and mammalian orthologues of Sprouty (Gross et al., 2001; Impagnatiello et al., 2001; Sasaki et al., 2001) signal to a number of RTKs as well as cytokine receptors coupled to non-receptor tyrosine kinases. Remarkably, mice carrying null copies of SOCS-1 (Alexander et al., 1999; Marine et al., 1999b) and SOCS-3 (Marine et al., 1999a) show developmental defects compatible with deregulated receptor function, as predicted by studies in cultured cells. Because of their physiological function, mammalian RTK inhibitors have been also proposed to exert tumorsuppressing activity (Fiorini et al., 2001) . Such a prediction has been validated by the finding that abnormal methylation of regulatory sequences silences transcription of SOCS-1 in human hepatocellular carcinomas (Yoshikawa et al., 2001 ). This appears to be relevant for tumor progression, as restoration of SOCS-1 expression in liver carcinoma cells inhibits their proliferation (Yoshikawa et al., 2001) . Cbl may also be involved in tumor suppression, as a Met mutant unable to bind Cbl acquires oncogenic properties (Peschard et al., 2001) . Finally, mSprouty1 has been identified as a target of the tumor suppressor WT1 (Gross et al., 2001) , a finding that raises the possibility that loss of mSprouty1 activity may be relevant to the pathogenesis of Wilms tumor.
The ErbB signaling network plays a crucial role in the regulation of a number of cellular programs, including cell proliferation, cell differentiation and cell locomotion (Yarden and Sliwkowski, 2001 ). Importantly, deranged activity of EGFR and ErbB-2 is causally linked to cell transformation. RALT (receptor associated late transducer), also known as gene33/Mig-6, (Lee et al., 1989; Wick et al., 1995) has been identified as a receptor -proximal inhibitor of mitogenic and transforming signals generated by ErbB receptors (Fiorentino et al., 2000; Hackel et al., 2001) . Over-expression studies indicate that RALT signals selectively to ErbB receptors, leaving mitogenic responses to serum, PMA and other mitogens unaffected (Fiorentino et al., 2000; Hackel et al., 2001) . Because its expression is induced by ErbB ligands, RALT has been categorized as a feedback inhibitor of ErbB RTKs, including EGFR, ErbB-4 and ErbB-2/ErbB-3 dimers (Fiorentino et al., 2000; Anastasi et al., submitted) . This raises the question of how ErbB signals regulate RALT expression and how cells use modulation of RALT expression to affect ErbB activity.
Herein, we show that physiological levels of RALT effectively suppress ErbB-2 mitogenic signals. We analyse pathways and mechanisms involved in the regulation of RALT expression and report that (a) activation of the Ras -Raf -ERK pathway by a number of stimuli is necessary and sufficient to drive expression of RALT in fibroblasts and epithelial cells; (b) the RALT protein is labile and is subjected to proteasome-dependent degradation. We propose that the integrated control of its expression provides RALT with the ability to promptly tune ErbB signals.
Results

Neutralization of RALT function enhances ErbB-2 mitogenic signals
A modest overexpression of RALT (about threefold over endogenous levels) is sufficient to inhibit EGFdependent proliferation of NIH-EGFR/ErbB-2 transfectants as well as focus formation induced by ErbB-2 in NIH3T3 cells (Fiorentino et al., 2000) . These results suggest that RALT normally functions as an inhibitor of ErbB-2 mitogenic signals. A corollary of this notion is that ablation of the expression or function of endogenous RALT should per se be sufficient to enhance the mitogenic activity of an EGFR/ErbB-2 chimeric receptor. We tested this hypothesis in the experiment shown in Figure 1 . NIH-EGFR/ErbB-2 cells were made quiescent by 24 h serum deprivation, and micro-injected with affinity-purified S1 rabbit polyclonal antibodies raised against a recombinant peptide spanning positions 282 -396 of the RALT protein (Fiorentino et al., 2000) . Following microinjection, cultures were stimulated with sub-optimal concentrations of either EGF or bFGF. Immunoblot analysis showed that bFGF was as effective as EGF in inducing expression of RALT (Figure 1a) . Progression of cells into S phase was monitored by immunohistochemical detection of bromo-deoxyuridine (BrdU) pulse-labeled cells. Upon stimulation with EGF (0.3 ng/ml) or bFGF (0.3 ng/ml) about 20% of uninjected EGFR/ErbB-2 cells entered S phase (data not shown). We observed a similar rate of entrance into S phase when counting cells microinjected with a control antiserum (RAM, Figure 1e ). Cells microinjected with anti-RALT antibodies and stimulated with EGF progressed to S phase at a frequency which was 2.8-fold higher than control cells. This effect was specific, as cells micro-injected with anti-RALT antibodies and challenged with bFGF showed only a weak, albeit reproducible, increase of their rate of entrance into S phase (1.5-fold). In contrast, blockade of the Ras pathway via microinjection of cells with the neutralizing Y13-259 anti-Ras monoclonal antibody (Mulcahy et al., 1985) inhibited entry into S phase of EGF-and bFGF-stimulated cells by 85% (data not shown). Because the S1 antiserum was raised against a peptide containing the ErbB-2 binding region of RALT as well as SH3 binding motifs (Fiorentino et al., 2000) we interpret the neutralizing activity of S1 antibodies as due to its ability to interfere with crucial aspects of RALT signaling to ErbB-2. We conclude that endogenous RALT protein behaves as a bona fide feedback inhibitor of the ErbB-2 kinase.
Identification of signaling pathways involved in the induction of RALT expression
Signaling by the ErbB-2 kinase induces expression of the RALT protein with a mechanism dependent on transcriptional activation of the RALT gene. Because the kinetics of accumulation of RALT mRNA are similar to those of immediate-early genes (Fiorentino et al., 2000) it is inferred that signaling pathways directly activated by ErbB-2 signals must regulate transcription of the RALT gene.
Major signaling pathways activated by ErbB-2 include the Ras -ERK pathway, PI-3K, PKC and p38/SAPK (reviewed in Harari and Yarden, 2000) . As shown in Figure 2a pharmacological inhibition of the ERK upstream activator MEK-1 with PD9859 (Alessi et al., 1995) caused a strong reduction of RALT protein expression in EGF-stimulated EGFR/ErbB-2 cells. This effect was specific, as pharmacological inhibitors of PI-3K (LY294002) (Vlahos et al., 1994) , Quiescent NIH -EGFRErbB2 cells were microinjected with rabbit anti-mouse IgGs (2.2 mg/ml) or affinity-purified rabbit anti-RALT IgGs (1.8 mg/ ml) and then stimulated with EGF (0.3 ng/ml) or bFGF (0.3 ng/ml) for 18 h. Cells were labeled with BrdU during the last 6 h. The mean fold increase or decrease in S phase entry was calculated (+s.e.) as fold stimulation of percentage of S phase entry in uninjected cells (taken as 1). The number of cells injected with each antibody is indicated above the corresponding bar, and the number of experiments is given in parenthesis Figure 2 Analysis of signaling pathways responsible for induction of RALT expression. (a) NIH -EGFR/ErbB-2 cells were made quiescent by 24 h serum deprivation and either lysed without further treatment (C) or stimulated for 4 h with 10% calf serum (NCS), 10 ng/ml EGF or 20 nM TPA. Where indicated, cell-permeant inhibitors were added to the culture medium 30 min prior to the start of mitogenic stimulation. Inhibitors were used at the following concentrations: PD9859 50 mM, LY294002 10 mM, SB203580 5 mM, Go6983 5 mM. Lysates were analysed by immunoblot with S1 anti-RALT antiserum and ECL detection. (b) HC-11 cells were made quiescent and either lysed without further treatment (C) or stimulated with 20 ng/ml TGF-a for 4 h (upper panel). Bottom panel shows a similar experiment in which quiescent HC-11 cells were subjected to osmotic stress (300 mM sorbitol) for 15 min and then incubated in mitogen-free medium for additional 4 h prior to lysis. Where indicated cell-permeant inhibitors were added to culture medium 30 min before TGF-a or sorbitol treatment. UO126 was used at 25 mM, PP2 was used at 3 mM, the other inhibitors were used at the same concentrations as in a. Lysates were analysed by immunoblot with the indicated antibodies (Douglas et al., 1999) and p38/SAPK (SB203580) (Schafer et al., 1998) did not affect the expression levels of RALT. PD9859 was able to suppress specifically the induction of RALT expression also in NIH -EGFR/ErbB-2 cells challenged with either the phorbol ester TPA or serum ( Figure 2a ). As predicted, in TPA stimulated cells the PKC inhibitor Go6983 completely blocked the induction of RALT expression (Figure 2a ). These observations were extended to HC-11 cells, a murine cell line derived from breast epithelium. In these cells TGF-a, an activator of EGFR, and HRG1b, which triggers ErbB-2/ErbB-3 dimers (Marte et al., 1995a,b) , are able to induce RALT expression (Fiorentino et al., 2000) . Two different inhibitors of MEK-1, namely PD9859 and U0126 (Davies et al., 2000) , caused a severe reduction of RALT expression in HC-11 cells challenged with TGF-a ( Figure 2b ). Such an effect was not observed with LY294002, Go6983 and SB203580. PP2, which inhibits Src family tyrosine kinases (Nagao et al., 1999) , was also included in these experiments, as Src is activated by EGFR (Luttrell et al., 1988) and ErbB-2 (Muthuswamy and Muller, 1995) . Treatment of HC-11 cells with PP2 had no consequence on the ability of TGF-a to induce expression of RALT (Figure 2b ).
Since RALT expression has been reported to be induced also by stressing stimuli (Makkinje et al., 2000) , we sought to identify signaling pathways that drive RALT expression in HC-11 cells subjected to osmotic stress. As shown in Figure 2b , inhibition of MEK-1 caused a marked reduction of sorbitol-induced RALT expression. In the same experiment, inhibition of p38/SAPK, Src, PKC and PI-3K had no consequence on the levels of RALT protein induced by osmotic stress. Ablation of RALT expression by MEK-1 inhibitors is caused by suppression of RALT transcription, as indicated by the Northern blot analysis presented in Figure 3 .
The information gained with the use of pharmacological inhibitors was complemented by the genetic analysis shown in Figure 4a . Quiescent NIH -EGFR/ ErbB-2 cells were infected with the indicated recombinant adenovirus stocks at similar m.o.i., and then stimulated with either EGF or TPA to induce RALT expression. Inhibition of Ras signaling by a dominant negative (DN) Ras N17 allele suppressed induction of RALT by both EGF and TPA. DN alleles of Src, MKK-6 (the upstream activator of p38) and a control adenovirus expressing green fluorescent protein (GFP) had no effect on RALT induction (Figure 4a ), despite being expressed at high levels (data not shown).
Collectively, the data presented in Figures 2 -4 suggest that in two different cell types signals of ErbB RTKs, which are necessary to the induction of RALT protein, are funneled via the Ras -ERK pathway. Moreover, induction of RALT by serum, TPA and sorbitol-mediated osmotic stress also depends on activation of the same pathway. An issue raised by the results described above is whether activation of the Ras/ERK pathway is sufficient to induce expression of RALT. This was addressed by using Raf : ER chimeric proteins in which the catalytic activity of Raf can be induced by stimulation with tamoxifen (Samuels et al., 1993) . We used the DD and YY Raf : ER alleles, which direct the expression of Raf kinases with different intrinsic catalytic potencies, DD Raf being about fivefold more active than YY Raf (Zhu et al., 1998) . NIH3T3 cells expressing either Raf : ER-DD or Raf : ER-YY synthesized RALT upon stimulation with Tamoxifen for 4 -8 h in serum-deprived medium (Figure 4b ). The effect of tamoxifen was as strong as serum stimulation and was reverted by the administration of U0126 (Figure 4b ), indicating that activation of MEK1 via Raf is sufficient to induce expression of RALT. Figure 3 Pharmacological inhibition of MEK1 suppresses transcriptional activation of RALT following EGFR/ErbB-2 activation. (a) After being made quiescent by 24 h serum deprivation, NIH -EGFR/ErbB-2 cells were either lysed or stimulated for 10 min with 10 ng/ml EGF prior to lysis. Where indicated culture medium was added either 30 mM LY294002 or 50 mM U0126 30 min prior to EGF stimulation. Lysates were immunoblotted with anti-phospho ERK or anti-phospho AKT antibodies. Reprobing with anti-ERK and anti-AKT antibodies confirmed that equal amounts of protein had been loaded in all lanes (not shown). (b) In the same experiment shown in a a similar complement of dishes was subjected to lysis after 3 h EGF stimulation. Lysates were immunoblotted with anti-RALT antibodies; the filter was stripped and re-probed with anti-SHC antiserum to control for loading of cell lysates. (c) A third complement of dishes was lysed after 1 h EGF stimulation. Total RNA was prepared and subjected to Northern blot analysis with a RALT cDNA probe. The filter was stripped and re-probed with a b-actin probe to control for loading of RNA samples
Stability of RALT protein is affected by proteasome inhibitors
The RALT protein contains two blocks of PEST sequences (Fiorentino et al., 2000) , a feature typical of labile proteins that may be degraded by the 26S proteasome (Huggins et al., 1999; Oberg et al., 2001; Salama et al., 1994; Wallace and Cidlowski, 2001 ). We therefore addressed whether inhibition of proteasome activity may stabilize RALT protein. As shown in Figure 5a ,b, treatment of NIH -EGFR/ErbB-2 cells with the proteasome inhibitor MG132 (Palombella et al., 1994 ) caused a striking increase in the steady-state levels of EGF-induced RALT protein. The effect of MG132 on RALT accumulation was observed as early as between 2 -4 h of EGF stimulation and persisted at later times. MG132-dependent RALT accumulation was most notable during the window of time corresponding to the peak of RALT expression in control cells. Remarkably, administration of MG132 after 12 h of EGF treatment, i.e. at a time in which expression of RALT in control cells dropped dramatically, was still able to cause accumulation of RALT to an extent comparable to that of control cells stimulated with EGF for 8 h. Two other proteasome inhibitors, i.e. LLnL (Hughes et al., 1996) and Lactacystin (Fenteany et al., 1995) , were equally effective in promoting RALT accumulation in EGFtreated NIH -EGFR/ErbB-2 cells, whereas the calpainspecific inhibitor ALLM (Blagosklonny et al., 1999) did not cause stabilization of RALT (data not shown), ensuring the specificity of our observations. Proteasome inhibitors caused time-dependent accumulation of RALT protein also in EGFR/ErbB-2 cells kept in mitogen-free medium (Figure 6 ). Under these conditions we observed accumulation of endogenous RALT protein (Figure 6a ) as well as of ectopically expressed RALT (Figure 6b ). Because proteasome inhibitors did not affect RALT mRNA levels (data not shown), these observations suggested that the RALT protein is intrinsically labile and that inhibition of proteasome activity affects directly RALT stability. This was formally addressed by pulse -chase experiments. Under (7) or presence (+) of 25 mM U0126. In the experiment shown in the middle panel quiescent cells were either lysed (C) or incubated for 15 min with mitogen-free medium containing 300 mM sorbitol and then cultured in mitogen-free medium for 4 h prior to lysis. In all of the panels NIH -EGFR/ErbB-2 cells infected with the indicated recombinant adenovirus stocks were made quiescent and lysed after EGF, sorbitol or TPA stimulation according to the time schedule described above. Samples were subjected to immunoblot analysis with anti-RALT polyclonal antibodies followed by ECL detection. (b) NIH3T3 cells expressing the indicated chimeras between the hormone binding domain of the estrogen receptor and Raf were made quiescent by 24 h serum deprivation. Cells were either lysed without further treatment (C) or stimulated for the indicated time with 10% serum (NCS) or 2 mM tamoxifen prior to lysis. Where indicated 25 mM U0126 was added to culture medium 30 min prior to serum or tamoxifen stimulation. Samples were subjected to immunoblot analysis with anti-RALT polyclonal antibodies followed by ECL detection (Figure 6c ). This was remarkably prolonged when pulse-labeled cultures were chased in the presence of proteasome inhibitors (Figure 6c ). Since ubiquitinylation is thought to be an essential step in the recognition of proteins by the proteasome (Hochstrasser, 1996) we investigated whether RALT is subjected to poly-ubiquitinylation. To this end we cotransfected 293 cells with expression vectors directing the synthesis of RALT and HA epitope-tagged ubiquitin, either individually or in combination (Figure 7) . Cell lysates were subjected to immunoprecipitation with anti-RALT antibodies and immuno-blot analysis with a MoAb against the HA epitope tag. Anti-HA immunoreactivity was present only in immunoprecipitates prepared with lysates of cells expressing both RALT and HA-ubiquitin and corresponded to species with a molecular weight compatible with RALT being subjected to polyubiquitinylation (Figure 7, right  panel) . Consistently, anti-HA immunoreactivity in anti-RALT immunoprecipitates was enhanced when cells were treated with MG132 prior to lysis, which led also to accumulation of RALT (as measured by immunoblot analysis of total cell lysates) (Figure 7 , left panel). We conclude that RALT undergoes polyubiquitinylation in intact cells.
Discussion
Previous studies have indicated that RALT is able to suppress ErbB-2 mitogenic and transforming signals upon over-expression in murine fibroblasts (Fiorentino et al., 2000) . Because RALT is able to complex with ErbB-2 in an activity-dependent fashion, it has been proposed that it functions as a receptor-proximal feedback inhibitor of ErbB-2 mitogenic signals (Fiorentino et al., 2000) . In the present study we complement previous studies with antibody microinjection experiments and demonstrate that ablation of the function of endogenous RALT enhances mitogenic signals of an EGFR/ErbB-2 chimeric receptor. These data provide formal validation that RALT is physiologically involved in negative signaling to ErbB-2.
RALT becomes expressed as an approximately linear function of ErbB-2 engagement (Fiorentino et al., 2000 , see also Figure 1a ). This suggests that under physiological conditions its expression levels are subordinate to the intensity of ErbB-2 signals. Reciprocally, ErbB-2 mitogenic activity is critically affected by relatively minor changes of RALT levels, as demonstrated by the following findings: (a) functional blockade of the small amounts of RALT expressed by cells stimulated with 0.3 ng/ml EGF (low receptor occupancy) leads to a marked increase of ErbB-2 mitogenic activity ( Figure 1) ; (b) even at high levels of ErbB-2 engagement, a modest (about threefold) excess of ectopic RALT over the endogenous protein is still capable to lead to a significant inhibition of ErbB-2 signals (Fiorentino et al., 2000) . These findings indicate that physiological variations of RALT expression caused by changes in the levels of ErbB-2 engagement are likely to affect ErbB-2 mitogenic signals to a proportional extent. We therefore propose that RALT behaves as a rheostat, which can adjust the intensity of ErbB-2 signals over a wide range of receptor activity. This function is likely to be critical during the G1 phase of the cell cycle, when continuous growth factor stimulation (Jones and Kazlauskas, 2001 ) and ensuing ERK activity (Chiariello et al., 2000; Pages et al., 1993) are required for progression into S phase. At the same time, however, excess Ras -ERK signals would cause G1 arrest (Woods et al., 1997) , which calls for an extremely tight regulation of ERK outputs in the face of continuous RTK stimulation.
Our studies indicate that upon engagement of ErbB receptors activation of the Ras -ERK pathway is necessary and sufficient to induce expression of RALT. This is indicated by: (a) the ability of pharmacological inhibitors of MEK1 to inhibit RALT expression; (b) the ability of a DN Ras allele to ablate RALT expression; (c) the ability of a conditional Raf : ER chimera to induce RALT expression when triggered with tamoxifen. On the other hand, either pharmacological or genetic interference with PI-3K, PKC, Src and p38/SAPK activities leaves RALT levels unaffected. Similar observations were made in cells stimulated with mitogens such as TPA and serum or challenged with osmotic stress.
A number of mitogenic stimuli activate the Ras -ERK pathway (Robinson and Cobb, 1997) , which explains why transcriptional activation of RALT appears to be a rather stereotyped response in cycling cells (Fiorentino et al., 2000; Lee et al., 1989; Wick et al., 1995) . mSprouty2 and mSprouty4 mRNAs also accumulate in response to FGF-2 and EGF in a manner which is sensitive to MEK1 inhibitors (Ozaki et al., 2001; Sasaki et al., 2001) . Remarkably, overexpression of mSprouty2 and mSprouty4 causes inhibition of ERK activation by FGF-2, but bears no consequence on EGF-dependent ERK activity (Impagnatiello et al., 2001; Sasaki et al., 2001) . Thus, the signaling specificity of RALT and mSprouty appears to conflict with the observation that a signaling cassette used by most RTKs controls their expression. While this could imply a default transcriptional activation of RTK feedback inhibitors by redundant receptor signals, we note that cells may be targeted simultaneously by different cytokines, growth factors and integrin ligands which all activate the Ras -ERK pathway (Robinson and Cobb, 1997) . Under these conditions signal amplification intrinsic to the catalytic Raf -MEK -ERK cascade may lead to super-additive outputs. It seems likely that the concomitant induction of feedback inhibitors targeting different RTKs has been selected as an efficient means of monitoring ERK activation under conditions causing additive or superadditive outputs from this pathway.
So far, the expression of RTK feedback inhibitors has been shown to be controlled exclusively at the transcriptional level. Herein, we introduce a novel level of regulation of a RTK feedback inhibitor by showing that RALT is subjected to proteasome-dependent degradation. Our data indicate that inhibition of proteasome activity leads to accumulation of RALT protein via direct regulation of its half-life. Thus, the short-lived profile of RALT mRNA accumulation is coupled to the intrinsic lability of the RALT protein.
We propose that cells resort to the integration of these control mechanisms to obtain finely balanced levels of RALT: while allowing RALT to tune ErbB signals, such a balance also avoids accumulation of excess amounts of RALT in G1 and provides for termination of RALT signals once cells enter S phase (Fiorentino et al., 2000) . It is unclear whether ErbB-2 signals may provide for additional regulation of RALT stability. When pulse-labeled EGFR/ErbB-2 cells were chased in the presence of EGF we did not observe substantial changes in the half-life of the RALT protein (data not shown). It is possible, however, that ErbB-2 signal can affect RALT stability both positively and negatively and that the balance of opposing signals could shift in either direction depending on the physio-pathological conditions of the cell. Thus, more detailed studies are needed to conclusively address this issue.
RALT is likely to be targeted to the proteasome by poly-ubiquitin tags, since we can detect poly-ubiquitinylated RALT species in living cells co-expressing RALT and HA-tagged ubiquitin. The regulatory steps that preside to RALT ubiquitinylation have not been detailed as yet. We hypothesize that the two blocks of PEST sequences present in the RALT protein are likely to act as key structural determinants of RALT lability by serving as recognition elements for the molecular machinery which diverts cellular proteins to the proteasome (Hochstrasser, 1996; Myung et al., 2001; Rechsteiner and Rogers, 1996) .
A recent report has shown that induction of RALT mRNA in A549 lung carcinoma cells subjected to mechanical stress could be prevented by ectopic expression of a DN JNK/SAPK allele (Makkinje et al., 2000) . We find that in NIH3T3 fibroblasts and HC-11 epithelial cells induction of RALT by osmotic stress is prevented by interference with the Ras -ERK pathway rather than by genetic or pharmacological blockade of a stress activated kinase such as p38. These apparent discrepancies may be accounted for by differences in stressing stimuli and cellular backgrounds. Osmotic stress may lead to trans-activation of EGFR (Rosette and Karin, 1996) , which is certainly consistent with the possibility that RALT expression in stressed cells is induced by Ras -ERK signals elicited by trans-activated EGFR.
In conclusion, we propose that RALT functions as a rheostat of ErbB mitogenic signals. A prime determinant of this function is the level of expression of RALT itself. Accumulation of RALT is controlled at least at two levels, namely gene transcription and protein stability. Signaling by Ras -ERK is necessary and sufficient to induce RALT transcription, whereas the ubiquitin/proteasome pathway regulates RALT protein levels. In cancer cells, ablation of expression of growth suppressors may be achieved by transcriptional silencing (Yoshikawa et al., 2001; Rountree et al., 2001) or abnormal degradation via the ubiquitin-proteasome pathway (Loda et al., 1997; Xu and Attisano, 2000; Spataro et al., 1998) . Further studies are warranted to investigate whether these regulatory steps of RALT expression are targeted in cancer cells in order to ablate RALT function and create a condition permissive for deregulated ErbB signaling.
Materials and methods
Materials
EGF was from Upstate Biotechnology, TGF-a was from R&D, gelatine, sorbitol, LLnL, tamoxifen and transferrin were from Sigma, PD9859, LY294002, SB203580, Go6983, MG132 and PP2 were from Calbiochem, U0126 was from Promega. Tissue culture media and sera were from Life Technologies.
Microinjection and cell proliferation assay
Prior to usage in microinjection experiments antibodies were dialysed extensively against calcium-free phosphate buffered saline (PBS) in a micro-dialysis chamber. Antibody final concentrations were as follows: Y13-259 anti-Ras monoclonal antibody 2.2 mg/ml; affinity-purified rabbit anti-mouse IgGs 2 mg/ml; rabbit anti-RALT IgGs (affinity-purified onto GST -RALT 282-396) 1.8 mg/ml. NIH -EGFR/ErbB-2 cells were plated onto collagen-coated 60 mm dishes, allowed to grow to 50 -70% confluence and rendered quiescent by 24 h serum deprivation. In each experiment 100 -200 cells per experimental group were injected with purified antibodies. Following microinjection, cells were stimulated with mitogens for 18 h; BrdU was added during the 12 -18 h interval. After incubation with BrdU, cells were fixed and stained using a cell proliferation assay kit (Amersham) as previously described (Gallo et al., 1997) . This time schedule was chosen after we had determined that NIH -EGFR/ErbB-2 cells initiated DNA duplication 12 h past the beginning of mitogenic stimulation.
Cell lines, cell culture conditions and gene transfer procedures NIH3T3 fibroblasts and NIH -EGFR -ErbB-2 transfectants (Fazioli et al., 1991) were grown in Dulbecco's modified minimal essential medium (D-MEM) containing 10% (vol/ vol) newborn calf serum. HC-11 murine mammary epithelial cells (Marte et al., 1995b) and 293 human embryonal kidney epithelial cells were grown in D-MEM containing 10% fetal calf serum. To induce quiescence, confluent monolayers of cells were rinsed twice with PBS and cultured for 24 h in mitogen-free medium (a 1.1 mixture of D-MEM and Ham's F-12 media, containing 0.2% serum, 10
77 Na 2 SeO 3 and 2 mg/ml transferrin). Transient transfections of 293 cells were performed using the calcium phosphate co-precipitation procedure described by Chen and Okayama (1987) . Cells were processed for immuno-precipitation experiments 36 h post-transfection. Expression of ectopic RALT in NIH -EGFR/ErbB-2 cells was obtained by infection with stocks of Pinco and Pinco -RALT recombinant retrovirus as described (Fiorentino et al., 2000) . Recombinant retrovirus stocks expressing Raf : ER chimeras (Woods et al., 1997) were generated in Bosc23 cells (Pear et al., 1993) . NIH3T3 cells infected with Raf : ER or control retrovirus stocks were selected with puromycin. Recombinant adenovirus expressing GFP and LacZ (supplied by M Crescenzi), RasN17 (supplied by L Parada), kinase-dead Src (supplied by B Berk), kinasedead MKK6 (supplied by J Han) were propagated in 293 cells as described (Latella et al., 2001) . Viral titer was determined by plaque formation assay using 293 cells and was expressed as plaque-forming units (Latella et al., 2001) . Infections were carried out for 1 h as described (Latella et al., 2001) . After virus removal, cells were grown for additional 24 h before being subjected to further experimental manipulations. We routinely used m.o.i. equal to or greater than 200; under these conditions we reproducibly detected expression of ectopic proteins in 480% of target cells with no observable cytotoxicity.
Northern analysis
Total RNA was extracted using the Trizol reagent (Life Technologies) according to manifacturer's instructions. RNA samples were size-fractionated by agarose electrophoresis, transferred onto nitrocellulose filters and processed for Northern hybridization. cDNA probes were labeled with 32 P-dCTP using a random priming procedure (Amersham, Pharmacia Biotech) as indicated by the manifacturer.
Immunochemical procedures
For Western blot analysis cells were lysed with ice-cold HNTG buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100) containing 1 mM sodium orthovanadate and a cocktail of freshly added protease inhibitors. Lysates were clarified by centrifugation at 48C in a table top centrifuge and their protein concentration assessed with the BCA kit (Pierce) as indicated by the manifacturer. Lysates were size fractionated by SDS -PAGE and transferred onto nitrocellulose filters. Filters were incubated for 1 h at 258C in NET buffer (150 mM NaCl, 5 mM EDTA, 0.05% Tween-20, 50 mM Tris-HCl pH 7.5) containing 3% (weight/volume) non-fat dry milk, rinsed with NET buffer and probed with primary antibodies diluted in NET buffer containing 0.2% gelatine (weight/volume). The affinitypurified anti-RALT S1 antiserum ( (Fiorentino et al., 2000) reacts against rat, mouse and human RALT species and was used at 2 mg/ml. Anti ERK, anti-p-ERK, anti-AKT and antip-AKT antibodies (New England Biolabs) were used at 1 mg/ ml, anti-SHC (Transduction Laboratories) and anti-vinculin (Sigma) antibodies were used at 0.5 mg/ml. The 12CA5 monoclonal antibody was used at 2 mg/ml, the 195C/4 monoclonal antibody, which recognizes only the rat RALT species (Fiorentino et al., 2000) , was used at 2 mg/ml. Following a 16 h incubation at 48C with primary antibodies, filters were washed extensively in NET buffer, reacted with appropriate horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) and processed for ECL detection (Amersham) as described (Fiorentino et al., 2000) .
For immuno-precipitations of ubiquitin-conjugated RALT molecules, 293 transfectants were solubilized in a buffer containing 50 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 1% SDS, 5 mM ethylmaleimide. Lysates were heated at 958C for 5 min, sonicated and centrifuged to remove particulate residues. Clarified lysate were diluted with nine volumes of ice-cold HNTG buffer and incubated for 2 h at 48C with purified 19C5/4 antibody covalently bound to Imunopure resin (Pierce) (20 mg antibody per mg of cell lysate). Immune complexes were washed extensively with lysis buffer and bound antigens released by heating samples at 958C after the addition of Laemmli buffer. Samples were size fractionated by SDS -PAGE, transferred onto nitrocellulose filters and analysed by immunoblot.
For pulse-chase experiments, NIH -EGFR/ErbB-2 cells infected with the Pinco -RALT retrovirus were seeded in 60 mm dishes. The next day cultures were serum-starved for 4 h, incubated for additional 45 min in D-MEM Met/Cysfree medium and labeled for 30 min at 378C with 0.3 mCi/ml of a mixture of 35 S-methionine and cystine. After removal of labeling medium, cultures were either lysed or chased in mitogen-free medium containing excess unlabeled methionine and cystine. When indicated, proteasome inhibitors were added to the culture medium. Cell lysates were subjected to immunoprecipitation with anti-RALT MoAb 19C5/4. Immunoprecipitates were resolved in 10% SDS -PAGE and processed for autoradiography. Quantitation of labeled RALT molecules was performed by PhosphorImager analysis.
